ANV-419
- Generic Name
- ANV-419
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Phase 1
Terminated
- Conditions
- Refractory Multiple MyelomaMultiple MyelomaAdult DiseaseRelapsed CancerHematologic Diseases
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Anaveon AG
- Target Recruit Count
- 4
- Registration Number
- NCT05641324
- Locations
- 🇩🇰
Vejle Hospital, Vejle, Denmark
🇫🇷CHU de Nantes - Hôtel-Dieu, Nantes, France
🇫🇷Institut Paoli-Calmettes, Marseille, France
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Phase 1
Completed
- Conditions
- Melanoma (Skin)Cutaneous MelanomaAdult DiseaseAdvanced Solid TumorMetastatic Melanoma
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Anaveon AG
- Target Recruit Count
- 29
- Registration Number
- NCT05578872
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
Phase 1
Completed
- Conditions
- Advanced Solid TumorAdult DiseaseLung Cancer
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Anaveon AG
- Target Recruit Count
- 55
- Registration Number
- NCT04855929
- Locations
- 🇪🇸
Hospital Vall d'Hebrón, Barcelona, Spain
🇪🇸START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain
🇨ðŸ‡University Hospital Basel, Basel, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath